Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation

Stroke

Volumn 44, Issue 6, 2013, Pages 1676-1681

  Harrington, Amanda R ^a   Armstrong, Edward P ^a   Nolan Jr , Paul E ^a   Malone, Daniel C ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Cost effectiveness; Intracranial hemorrhage; Markov model; Stroke

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

ARTICLE; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; CREATININE CLEARANCE; HEART ATRIUM FIBRILLATION; HUMAN; KIDNEY CLEARANCE; LONG TERM CARE; MONTE CARLO METHOD; NONVALVULAR ATRIAL FIBRILLATION; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RISK ASSESSMENT;

ANTICOAGULATION; ATRIAL FIBRILLATION; COST-EFFECTIVENESS; INTRACRANIAL HEMORRHAGE; MARKOV MODEL; STROKE;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COHORT STUDIES; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MARKOV CHAINS; MODELS, STATISTICAL; MORPHOLINES; PYRAZOLES; PYRIDONES; QUALITY-ADJUSTED LIFE YEARS; RISK FACTORS; STROKE; THIOPHENES; UNITED STATES; WARFARIN;

EID: 84880141189     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.111.000402     Document Type: Article

References (40)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fbrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
2. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Executive summary: heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123:459-463.
3. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al; American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123:933-944.
4. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke. 1996;27:1459-1466.
5. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125:e2-e220.
6. Lee WC, Christensen MC, Joshi AV, Pashos CL. Long-term cost of stroke subtypes among Medicare benefciaries. Cerebrovasc Dis. 2007;23:57-65.
7. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost. 2004;91:87-94.
8. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fbrillation. N Engl J Med. 2011;365:981-992.
9. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fbrillation. N Engl J Med. 2009;361:1139-1151.
10. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fbrillation. N Engl J Med. 2011;365:883-891.
11. Shah S V, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fbrillation. Circulation. 2011;123:2562-2570.
12. Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fbrillation. Ann Intern Med. 2011;154:1-11.
13. Kamel H, Johnston SC, Easton JD, Kim AS. Cost-effectiveness of dab-igatran compared with warfarin for stroke prevention in patients with atrial fbrillation and prior stroke or transient ischemic attack. Stroke. 2012;43:881-883.
14. Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fbrillation. Am J Cardiol. 2012;110:845-851.
15. Kamel H, Easton JD, Kim AS. Cost-effectiveness of apixaban vs. warfarin for secondary stroke prevention in atrial fbrillation. Neurology. 2012;79:1428-1434.
16. Neumann PJ, Sandberg EA, Bell CM, Stone PW, Chapman RH. Are pharmaceuticals cost-effective? A review of the evidence. Health Aff (Millwood). 2000;19:92-109.
17. TreeAge Pro, Inc. (TreeAge Pro Suite) [Computer Program]. Williamstown, MA: TreeAge Pro, Inc; 2012.
18. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identifed events in the RE-LY trial. N Engl J Med. 2010;363:1875-1876.
19. Laupacis A, Boysen G, Connolly S, Ezekowitz M, Hart R, James K, et al. Risk factors for stroke and effcacy of antithrombotic therapy in atrial fbrillation. Analysis of pooled data from fve randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
20. Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long-term survival after frst-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993;24:796-800.
21. Kannel WB, Sorlie P, McNamara PM. Prognosis after initial myocardial infarction: the Framingham study. Am J Cardiol. 1979;44:53-59.
22. Agency for Healthcare Research and Quality. National and regional estimates on hospital use for all patients from the HCUP Nationwide Inpatient Sample (NIS). Healthcare Cost and Utilization Project online (HCUPnet). http://hcupnet.ahrq.gov/. Publication date 2009. Accessed May 11, 2012.
23. Earnshaw SR, Scheiman J, Fendrick AM, McDade C, Pignone M. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med. 2011;171:218-225.
24. Arias E. United States life tables, 2007. Natl Vital Stat Rep. 2011;59:1-60.
25. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996;156:1829-1836.
26. Sullivan PW, Ghushchyan V. Preference-Based EQ-5D index scores for chronic conditions in the United States. Med Decis Making. 2006; 26:410-420.
27. Pignone M, Earnshaw S, Pletcher MJ, Tice JA. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis. Arch Intern Med. 2007;167:290-295.
28. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care. 2005;43:736-749.
29. Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics. 2003;21:191-200.
30. Roche Diagnostics & American Medical Association. 2009 Medicare reimbursement handbook for healthcare professionals. http://www.poc.roche.com/ en-US/pdf/44156-Coag2009Handbook-FINAL- APPROVED.pdf. Publication date 2009. Accessed July 23, 2012.
31. National Health Service. Apixaban for the prevention of venous throm-boembolism after total hip or knee replacement in adults: costing statement, implementing NICE guidance. http://www.nice.org.uk/nicemedia/live/ 13648/57919/57919.pdf. Publication date 2012. Accessed July 23, 2012.
32. Leibson CL, Hu T, Brown RD, Hass SL, O'Fallon WM, Whisnant JP. Utilization of acute care services in the year before and after frst stroke: a population-based study. Neurology. 1996;46:861-869.
33. Jonas DE, Bryant Shilliday B, Laundon WR, Pignone M. Patient time requirements for anticoagulation therapy with warfarin. Med Decis Making. 2010;30:206-216.
34. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. J Am Med Assoc. 1996;276:1253-1258.
35. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17:479-500.
36. Freeman WD, Kuo R, Aguilar MI. Letter by Freeman et al regarding article, "Intracranial hemorrhage in atrial fbrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY Trial." Stroke. 2012;43:e63.
37. Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fbrillation in UK context: quantitative beneft-harm and economic analyses. BMJ. 2011;343:d6333.
38. Rose AJ, Hylek EM, Ozonoff A, Ash AS, Reisman JI, Berlowitz DR. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). J Thromb Haemost. 2010;8:2182-2191.
39. van Walraven C, Jennings A, Oake N, Fergusson D, Forster AJ. Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest. 2006;129:1155-1166.
40. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, et al; ACTIVE W Investigators. Beneft of oral anticoagulant over antiplatelet therapy in atrial fbrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118:2029-2037.